Application of ginsenoside Rg5 in resisting melanoma

A ginsenoside and anti-melanin technology, applied in the field of biomedicine, can solve the problems that the influence of melanoma cell growth is not clear or not

Pending Publication Date: 2022-01-18
GUANGDONG PHARMA UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Aiming at the deficiencies in the prior art, the present invention provides the application of ginsenoside Rg5 in anti-melanoma, which solves the problem: the influence on the growth of melanoma cells is not clear at present, and there is no related research, which can prove that ginsenoside Rg5 has an effect on melanoma. Antiproliferative effects and mechanism of action on tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ginsenoside Rg5 in resisting melanoma
  • Application of ginsenoside Rg5 in resisting melanoma
  • Application of ginsenoside Rg5 in resisting melanoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Antiproliferative effect of ginsenoside Rg5 on mouse skin melanoma cells B16F10.

[0028] The effect of Rg5 on the proliferation of mouse skin melanoma cells B16F10 was evaluated by MTT assay and morphological observation. Mouse skin melanoma cells B16F10 in the logarithmic growth phase were seeded in a 96-well plate at a density of 5x103 cells / well, with 100 μl of medium per well. After 24 hours, the cells were completely attached to the wall, and the treatment groups were given different concentrations of Rg5 for 24 hours and 48 hours, respectively. The administration concentrations of Rg5 were 1, 3, 10, 30, 100, 300 μmol / L, respectively. After the drug intervention was completed, the morphology of living cells was observed under a microscope. Discard the old medium, wash the cells with PBS, add 10 μl of MTT reagent (5.0 mg / ml) to each well, and incubate at 37°C for 4 hours in the dark. After incubation, add 100 μl DMSO to each well and shake well. Using a micropl...

Embodiment 2

[0032] Inhibitory migration of mouse skin melanoma cells B16F10 by Rg5.

[0033] The cell scratch test was used to evaluate the inhibitory effect of Rg5 on cell migration of mouse skin melanoma cells B16F10 treated for 12h and 24h. Take a 6-well plate, draw 5 parallel lines with a marker pen at the bottom of the 6-well plate, take mouse skin melanoma cells B16F10 in the logarithmic growth phase, and inoculate them in a 6-well plate at an appropriate density. After 24 hours, the cell fusion rate When it reaches 100%, use a 200 μl pipette tip to scratch the cells perpendicular to the parallel line at the bottom of the 6-well plate, wash the cells three times with PBS, and wash away the scratched dead cells. Serum-free medium was added to the control group, serum-free medium containing different concentrations of Rg5 was added to the treatment group, and the scratch widths of each group were photographed under an inverted microscope at 0h, 12h, and 24h, and five corresponding scr...

Embodiment 3

[0036] Pro-apoptotic effect of ginsenoside Rg5 on mouse skin melanoma cells B16F10.

[0037] DAPI staining and flow cytometry were used to evaluate the effects of different concentrations on the apoptosis of mouse skin melanoma cells B16F10 after 24 hours of exposure. Mouse skin melanoma cells B16F10 in the logarithmic growth phase were inoculated in 6-well plates and used Different concentrations of ginsenoside Rg5 were processed. After 24 hours of drug action, wash with PBS three times and fix with 4% paraformaldehyde for 1 hour. Use DAPI reagent to seal the slides at room temperature, and after drying, observe the cells under a microscope and collect image data.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of ginsenoside Rg5 in resisting melanoma, the ginsenoside Rg5 and application of the ginsenoside Rg5 in preparing anti-melanoma medicines. The invention proves that the ginsenoside Rg5 has the effects of inhibiting proliferation, inhibiting migration and promoting apoptosis on mouse skin melanoma cells B16F10, clarifies the action mechanism of the ginsenoside Rg5 in inhibiting melanoma from the molecular level, and can be used for treating melanoma diseases.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of ginsenoside Rg5 in anti-melanoma. Background technique [0002] Melanoma (Melanoma) is a malignant tumor caused by melanocytes. Although melanoma is uncommon compared with other skin cancers, accounting for only 4% of skin cancer cases, it is a very deadly disease. 75% of cancer deaths. In the United States, melanoma affects only 22.1 people per 100,000 people. In my country, the number of patients with melanoma is doubling every 6-10 years. Its strong invasiveness and early metastasis make its mortality rate the highest among malignant skin tumors. The 5-year survival rate of patients with stage IV Only 6%. In addition to the skin, melanoma can also occur in any non-skin site where normal melanocytes appear, including the eyes, gastrointestinal tract, genitourinary system, and nasopharynx. [0003] Melanoma is more common in middle-aged and elderly peop...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K36/258A61P35/00A61P35/04
CPCA61K31/704A61K36/258A61P35/00A61P35/04
Inventor 何新纪瑞锋
Owner GUANGDONG PHARMA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap